Wall Street analysts expect that American Renal Associates Holdings Inc (NYSE:ARA) will announce earnings of $0.17 per share for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for American Renal Associates’ earnings, with the highest EPS estimate coming in at $0.19 and the lowest estimate coming in at $0.15. American Renal Associates reported earnings of $0.16 per share during the same quarter last year, which indicates a positive year over year growth rate of 6.3%. The business is scheduled to announce its next earnings results on Tuesday, August 14th.

On average, analysts expect that American Renal Associates will report full-year earnings of $0.70 per share for the current financial year, with EPS estimates ranging from $0.66 to $0.75. For the next financial year, analysts forecast that the company will report earnings of $0.78 per share, with EPS estimates ranging from $0.65 to $0.90. Zacks’ EPS averages are an average based on a survey of analysts that cover American Renal Associates.

American Renal Associates (NYSE:ARA) last announced its quarterly earnings results on Tuesday, May 8th. The company reported $0.11 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.09 by $0.02. The firm had revenue of $194.67 million for the quarter, compared to the consensus estimate of $189.10 million. American Renal Associates had a return on equity of 16.88% and a net margin of 0.60%. The company’s quarterly revenue was up 10.0% on a year-over-year basis. During the same period in the prior year, the company posted $0.07 earnings per share.

A number of research analysts have recently issued reports on the company. Zacks Investment Research downgraded American Renal Associates from a “hold” rating to a “sell” rating in a report on Tuesday, May 8th. Leerink Swann reaffirmed a “market perform” rating and set a $22.00 price target (down from $27.00) on shares of American Renal Associates in a report on Wednesday, April 25th.

Shares of American Renal Associates traded up $0.19, reaching $16.48, during midday trading on Wednesday, Marketbeat reports. 87,036 shares of the company’s stock traded hands, compared to its average volume of 162,633. The company has a market cap of $526.78 million, a P/E ratio of 27.00, a PEG ratio of 0.79 and a beta of 2.08. The company has a debt-to-equity ratio of 4.63, a current ratio of 1.15 and a quick ratio of 1.10. American Renal Associates has a one year low of $9.91 and a one year high of $24.07.

Several large investors have recently made changes to their positions in ARA. We Are One Seven LLC bought a new position in shares of American Renal Associates during the fourth quarter valued at $131,000. The Manufacturers Life Insurance Company increased its position in American Renal Associates by 897.0% during the fourth quarter. The Manufacturers Life Insurance Company now owns 9,302 shares of the company’s stock valued at $162,000 after acquiring an additional 8,369 shares during the last quarter. Element Capital Management LLC purchased a new stake in American Renal Associates during the first quarter valued at $263,000. Stone Ridge Asset Management LLC purchased a new stake in American Renal Associates during the fourth quarter valued at $325,000. Finally, Engineers Gate Manager LP purchased a new stake in American Renal Associates during the first quarter valued at $342,000. 89.40% of the stock is currently owned by hedge funds and other institutional investors.

American Renal Associates Company Profile

American Renal Associates Holdings, Inc operates as a dialysis services provider in the United States. It operates dialysis clinics focusing on joint venture partnerships with physicians. The company offers kidney dialysis services to patients suffering from chronic kidney failure or end stage renal disease.

Get a free copy of the Zacks research report on American Renal Associates (ARA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for American Renal Associates (NYSE:ARA)

Receive News & Ratings for American Renal Associates Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for American Renal Associates and related companies with MarketBeat.com's FREE daily email newsletter.